Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be lasting problem.
You may also be interested in...
Wall Street Sees Woodcock Commissionership As Positive for Aducanumab, But Eyes Should Be On Cavazzoni
Review extension for Alzheimer’s candidate may be positive for Biogen, but it’s not because Woodcock is acting commissioner. To understand the odds, it may be time to get to better know a new generation of US FDA’s drug review leadership.
Woodcock, Marks Recusals From COVID-19 Product Reviews 'Protect FDA's Reputation'
FDA experts say there is deep bench in CDER and CBER to tackle review questions while directors Janet Woodcock and Peter Marks help lead Operation Warp Speed; regulatory community is 'reassured' they will oversee advancement of COVID-19 therapeutics and vaccines.
Hahn May Not Run Into Questions About Industry Ties Like His Predecessors
Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.